
Opinion|Videos|December 8, 2025
Integrating Patient Reported Outcomes to Capture Meaningful Clinical Benefit
Author(s)Fiona C. Baker, PhD
Fiona C. Baker, PhD, emphasizes the importance of patient-reported outcomes in assessing elinzanetant’s overall benefit, including insights on symptom recurrence and quality-of-life improvements.
Advertisement
Episodes in this series

This discussion highlights the essential role of patient-reported outcomes in assessing treatment success, since women’s perceptions of reduced awakenings, improved sleep quality, and less severe hot flashes directly influence daytime functioning and help-seeking behavior. Objective polysomnography results in NIRVANA—showing reductions in wakefulness and improved sleep continuity—provide strong corroboration of these subjective gains. The dual confirmation strengthens confidence in the therapy’s impact on real-world quality of life.
Advertisement
Related to this article

ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.

Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.

Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.

Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.

NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.

Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.

Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
3
Susan Reed, MD, on the future of menopause research and funding
4
Matthew Nudy, MD, on estrogen and the cardiovascular system
5

